Toggle Summary
|
Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist
|
View HTML
|
Toggle Summary
|
Minerva Neurosciences to Present at Upcoming Investor Conferences in June
|
View HTML
|
Toggle Summary
|
Minerva Neurosciences Announces Appointment of Dr. Fouzia Laghrissi-Thode to Its Board of Directors
|
View HTML
|
Toggle Summary
|
Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates
|
View HTML
|
Toggle Summary
|
Minerva Neurosciences to Host First Quarter 2015 Financial Results Webcast and Conference Call
|
View HTML
|
Toggle Summary
|
Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results
|
View HTML
|
Toggle Summary
|
Minerva Neurosciences to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call
|
View HTML
|
Toggle Summary
|
Minerva Neurosciences Completes Private Placement, Raises $31 Million
|
View HTML
|
Toggle Summary
|
Minerva Neurosciences Announces $31 Million Financing
|
View HTML
|
Toggle Summary
|
Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
|
View HTML
|